Fig. 2

MTX treatment increases the level of p-YAP and alleviates the expression of YAP target genes and inflammatory factors. a HUVECs were treated with MTX (0–100 nM) and p-AMPK was quantified after 48 h by a western blot analysis. ***p < 0.001, ****p < 0.0001 vs. control. b qRT-PCR analysis of YAP/TAZ target genes and inflammatory factors for different flows. Results are presented as mean ± SD from three independent experiments from each group. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. STA (static), and ^#p < 0.05, ^##p < 0.01 vs. DF. c HUVECs were treated with or without MTX (100 nM) under USS, and p-YAP (Ser127) was quantified by western blot analysis. **p < 0.01,***p < 0.001 vs. STA. d HUVECs were treated with or without MTX under STA or DF, and p-YAP (Ser127) was quantified by western blot analysis. *p < 0.05, ****p < 0.0001 vs. STA; ^#p < 0.05 vs. STA + MTX